Integrated genomic and epigenomic analysis of blood circulating tumor DNA for pancreatic cancer - COSMOS-PC-01

ational Cancer Center Hospital East0 个研究点目标入组 500 人开始时间: 2020年5月21日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1. A history of malignancy with a disease-free period of up to 5 years.*1 2. Clinically suspected coexistence of cancer of other organs. 3. Women who are pregnant or intend to become pregnant. 4. Your physician determines that you are unsuitable for enrollment in the study. *1 Even if the disease-free period is less than 5 years, a history of cancer with a 5-year relative survival rate equivalent to 95% or higher, such as stage I prostate cancer, stage 0 and stage I laryngeal cancer with complete response to radiotherapy, and completely resected cancer in the following pathological stages, is not excluded and can be registered. Gastric cancer (adenocarcinoma (general type)): stage 0-I, colon cancer (adenocarcinoma): stage 0-I, rectal cancer (adenocarcinoma): stage 0-I, esophageal cancer (squamous cell carcinoma, adenosquamous cell carcinoma, basal cell carcinoma): stage 0, breast cancer (non-invasive ductal carcinoma, non-invasive lobular carcinoma): stage 0, breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget's disease): stage 0-IIA Cancer of the uterus (endometrial adenocarcinoma, mucinous adenocarcinoma): stage IA, prostate cancer (adenocarcinoma): stage I-II, cervical cancer (squamous cell carcinoma): stage IA, thyroid cancer (papillary carcinoma, follicular carcinoma): stage I, II, III, renal cancer (panniculocellular carcinoma, anaplastic pigment cell carcinoma): stage I, other intramucosal cancer equivalent lesions

发起方

ational Cancer Center Hospital East